{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:07:07Z","timestamp":1793110027022,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone is indicated in the United States for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Results from the FIDELIO-DKD and FIGARO-DKD Phase 3 clinical trials showed a statistically significant reduction in the risk of CKD progression and cardiovascular events with finerenone versus placebo when added to maximally tolerated dose of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The cardiovascular event risk reduction was primarily driven by the reduction in the risk of hospitalization for heart failure (HF). Recent results from the Phase 3 FINEARTS-HF trial in patients with HF with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) showed a significantly lower rate of a composite of total worsening HF events and death from cardiovascular causes with finerenone versus placebo. Further Phase 3 trials in additional HF populations are ongoing. The steroidal MRAs spironolactone and eplerenone are included in clinical practice guidelines for the treatment of symptomatic HF, but the highest class (grade 1) recommendations are in HF\u00a0with reduced ejection fraction\u00a0only. Based on the available evidence, finerenone presents as a new evidence-based therapy for HFpEF\/HFmrEF in addition to its current application in CKD associated with T2D. The aim of our review article is to present the current evidence available on the potential kidney and cardioprotective effects of finerenone to inform healthcare professionals (particularly those who work in cardiology).<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s10741-025-10520-3","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T01:02:42Z","timestamp":1748653362000},"page":"971-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment"],"prefix":"10.1007","volume":"30","author":[{"given":"Pam R.","family":"Taub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"10","key":"10520_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","volume":"11","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B et al (2023) Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF. JACC Heart Fail 11(10):1320\u20131332","journal-title":"JACC Heart Fail"},{"key":"10520_CR2","unstructured":"National Institutes of Health. Kidney disease statistics for the United States. 2023 18 November 2024]; Available from: https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease."},{"issue":"2","key":"10520_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10741-023-10346-x","volume":"29","author":"AI Guaricci","year":"2024","unstructured":"Guaricci AI et al (2024) Assessment and management of heart failure in patients with chronic kidney disease. Heart Fail Rev 29(2):379\u2013394","journal-title":"Heart Fail Rev"},{"issue":"7","key":"10520_CR4","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1681\/ASN.2019121308","volume":"31","author":"GA Nichols","year":"2020","unstructured":"Nichols GA et al (2020) Health care costs by type of expenditure across eGFR stages among patients with and without diabetes, cardiovascular disease, and heart failure. J Am Soc Nephrol 31(7):1594\u20131601","journal-title":"J Am Soc Nephrol"},{"key":"10520_CR5","unstructured":"Naha S et al (2021) Hypertension in diabetes. 18 November 2024]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279027\/"},{"issue":"2","key":"10520_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161","journal-title":"Eur Heart J"},{"issue":"8","key":"10520_CR7","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/jcm9082359","volume":"9","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis S, Mallamaci F, Zoccali C (2020) Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: A 2020 update. J Clin Med 9(8):2359","journal-title":"J Clin Med"},{"issue":"7","key":"10520_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","volume":"44","author":"T Ghatage","year":"2021","unstructured":"Ghatage T et al (2021) Novel therapeutics for the treatment of hypertension and its associated complications: Peptide- and nonpeptide-based strategies. Hypertens Res 44(7):740\u2013755","journal-title":"Hypertens Res"},{"issue":"6","key":"10520_CR9","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.3390\/ijms24065089","volume":"24","author":"G Gallo","year":"2023","unstructured":"Gallo G, Lanza O, Savoia C (2023) New insight in cardiorenal syndrome: From biomarkers to therapy. Int J Mol Sci 24(6):5089","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10520_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH et al (2022) Diabetes management in chronic kidney disease: a consensus report by the american diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int 102(5):974\u2013989","journal-title":"Kidney Int"},{"issue":"1","key":"10520_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP (2023) The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol 22(1):195","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10520_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J et al (2021) Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation 143(11):1157\u20131172","journal-title":"Circulation"},{"key":"10520_CR13","unstructured":"Centers for Disease Control and Prevention (2024) Risk factors for chronic kidney disease. 18 November 2024. Available from: https:\/\/www.cdc.gov\/kidney-disease\/risk-factors\/index.html"},{"key":"10520_CR14","unstructured":"Centers for Disease Control and Prevention (2024) About heart failure. 18 November 2024. Available from: https:\/\/www.cdc.gov\/heart-disease\/about\/heart-failure.html"},{"issue":"2","key":"10520_CR15","doi-asserted-by":"publisher","first-page":"e030131","DOI":"10.1161\/JAHA.123.030131","volume":"13","author":"JI Barzilay","year":"2024","unstructured":"Barzilay JI, Farag YMK, Durthaler J (2024) Albuminuria: An underappreciated risk factor for cardiovascular disease. J Am Heart Assoc 13(2):e030131","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"10520_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296\u20131305","journal-title":"N Engl J Med"},{"issue":"20","key":"10520_CR17","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE et al (2023) Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation 148(20):1606\u20131635","journal-title":"Circulation"},{"issue":"11","key":"10520_CR18","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK et al (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140(11):e596\u2013e646","journal-title":"Circulation"},{"key":"10520_CR19","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice, C., 11 (2025) Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S239-S251","DOI":"10.2337\/dc25-S011"},{"key":"10520_CR20","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice, C., 10 (2025) Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S207-S238.","DOI":"10.2337\/dc25-S010"},{"key":"10520_CR21","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice, C., 6 (2025) Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S128-S145.","DOI":"10.2337\/dc25-S006"},{"issue":"18","key":"10520_CR22","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"37","key":"10520_CR23","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA et al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"key":"10520_CR24","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios CJ et al (2023) Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev 9:e14","journal-title":"Card Fail Rev"},{"key":"10520_CR25","unstructured":"Golla MS, Shams P (2024) Heart failure with preserved ejection fraction (HFpEF). 18 November 2024]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599960\/"},{"key":"10520_CR26","unstructured":"Food and Drug Adminstration. Kerendia (finerenone) highlights of prescribing information. 2022 18 November 2024]; Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215341s001lbl.pdf."},{"issue":"27","key":"10520_CR27","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37(27):2105\u201314","journal-title":"Eur Heart J"},{"issue":"31","key":"10520_CR28","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463","journal-title":"Eur Heart J"},{"key":"10520_CR29","doi-asserted-by":"crossref","unstructured":"Kidney Disease: improving global outcomes diabetes work group, KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int, 2022 102(5S):S1-S127","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10520_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485","journal-title":"N Engl J Med"},{"issue":"10","key":"10520_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341(10):709\u201317","journal-title":"N Engl J Med"},{"issue":"14","key":"10520_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309\u20131321","journal-title":"N Engl J Med"},{"issue":"15","key":"10520_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"key":"10520_CR34","unstructured":"Scott JH, Menouar MA, Dunn RJ (2023) Physiology, aldosterone. 18 November 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470339\/"},{"issue":"4","key":"10520_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71(4):599\u2013608","journal-title":"Hypertension"},{"issue":"39","key":"10520_CR36","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart J et al (2010) A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285(39):29932\u201329940","journal-title":"J Biol Chem"},{"issue":"8","key":"10520_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L et al (2012) Discovery of BAY 94\u20138862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7(8):1385\u20131403","journal-title":"ChemMedChem"},{"issue":"36","key":"10520_CR38","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L et al (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 290(36):21876\u201321889","journal-title":"J Biol Chem"},{"key":"10520_CR39","unstructured":"Patibandla S, Heaton J, Kyaw H (2023) Spironolactone. 18 November 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554421\/"},{"issue":"13","key":"10520_CR40","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179(13):3220\u20133234","journal-title":"Br J Pharmacol"},{"key":"10520_CR41","unstructured":"Food and Drug Adminstration (2018) Aldactone (spironolactone) highlights of prescribing information. 18 November 2024. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf"},{"issue":"1","key":"10520_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64(1):69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"10520_CR43","first-page":"1801","volume":"22","author":"D Platt","year":"1972","unstructured":"Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of 3 H-spironolactone in animals. Arzneimittelforschung 22(10):1801\u20131802","journal-title":"Arzneimittelforschung"},{"key":"10520_CR44","unstructured":"Food and Drug Adminstration (2003) INSPRA (eplerenone) review and evaluation of pharmacology and toxicology data. 18 November 2024. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-437S002_Inspra_Pharmr.pdf"},{"key":"10520_CR45","unstructured":"Food and Drug Adminstration (2008) INSPRA (eplerenone) highlights of prescribing information. 18 November 2024. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021437s006lbl.pdf"},{"issue":"23","key":"10520_CR46","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.3390\/jcm10235483","volume":"10","author":"A Montagnani","year":"2021","unstructured":"Montagnani A et al (2021) Optimization of RAASi Therapy with new potassium binders for patients with heart failure and hyperkalemia: Rapid review and meta-analysis. J Clin Med 10(23):5483","journal-title":"J Clin Med"},{"issue":"4S","key":"10520_CR47","first-page":"S117","volume":"105","author":"K Disease","year":"2024","unstructured":"Disease K (2024) Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"23","key":"10520_CR48","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"24","key":"10520_CR49","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263","journal-title":"N Engl J Med"},{"issue":"9","key":"10520_CR50","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884\u2013894","journal-title":"JAMA"},{"issue":"6","key":"10520_CR51","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484","journal-title":"Eur Heart J"},{"issue":"12","key":"10520_CR52","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY analysis. Diabetes Care 45(12):2991\u20132998","journal-title":"Diabetes Care"},{"issue":"6","key":"10520_CR53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G et al (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial. Circulation 145(6):437\u2013447","journal-title":"Circulation"},{"issue":"6","key":"10520_CR54","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996\u20131005","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10520_CR55","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G et al (2022) Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail 10(11):860\u2013870","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10520_CR56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T et al (2021) Apararenone in patients with diabetic nephropathy: Results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol 25(2):120\u2013130","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10520_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpdd.855","volume":"10","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Kawaguchi A (2021) Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers. Clin Pharmacol Drug Dev 10(4):353\u2013365","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10520_CR58","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","volume":"26","author":"CSP Lam","year":"2024","unstructured":"Lam CSP et al (2024) Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial. Eur J Heart Fail 26(8):1727\u20131735","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10520_CR59","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1124\/dmd.122.001240","volume":"51","author":"B Lindmark","year":"2023","unstructured":"Lindmark B et al (2023) Mass balance and absorption, distribution, metabolism, and excretion properties of balcinrenone following oral administration in combination with intravenous microtracer in healthy subjects. Drug Metab Dispos 51(8):995\u20131004","journal-title":"Drug Metab Dispos"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10520-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:40:31Z","timestamp":1757184031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10520-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["10520"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10520-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not contain original clinical or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Pam R. Taub is a consultant for Sanofi, Novo-Nordisk, Novartis, Boehringer-Ingelheim, Amgen, Bayer, Lilly, Medtronic, Jazz, Lilly, and Esperion. Dr. Stephen J. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo and Tricog Health; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, Novo Nordisk, and Roche Diagnostics. Dr. Marat Fudim is a consultant to Bayer, unrelated to present project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}